SCHEMBL4407216

SCHEMBL4407216

Cc1ccc(OP(Cl)Cl)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ACHE P22303 1/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
MAPT P10636 1/20 0.36
HPGD P15428 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
MEN1 O00255 1/20 0.35
TRPA1 O75762 1/20 0.34
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4403529 0.87 L3MBTL1 (0.44) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL20798533 0.83 TP53 (0.40) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL470419 0.82 ACHE (0.44) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL17792449 0.80 ACHE (0.43) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL18812610 0.79 L3MBTL1 (0.41) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL7950326 0.78 ACHE (0.41) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL8385833 0.78 TP53 (0.43) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL3872825 0.78 TP53 (0.43) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL14277678 0.77 ACHE (0.45) TP53TDP1ACHEL3MBTL1SMN1; SMN2
SCHEMBL11445579 0.77 ACHE (0.40) TP53TDP1ACHEL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2395010-B1 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA Technologies S à r l (CH) 2016-07-13 EP disclosed
EP-1996598-B1 METHOD FOR THE PURIFICATION OF TRIORGANOPHOSPHITES BY TREATMENT WITH A BASIC ADDITIVE INVISTA TECH SARL (CH) 2013-10-16 EP disclosed
US-8178711-B2 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A R.L. (US) 2012-05-15 US disclosed
US-8178711-B2 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A R.L. (US) 2012-05-15 US disclosed
EP-1567468-B1 A SELECTIVE SYNTHESIS OF ORGANOPHOSPHITES INVISTA TECH SARL (CH) 2011-03-16 EP disclosed
US-20100076212-A1 METHOD FOR THE PURIFICATION OF TRIORGANOPHOSPHITES BY TREATMENT WITH A BASIC ADDITIVE INVISTA NORTH AMERICA S.A R.L. (US) 2010-03-25 US disclosed
US-20100076212-A1 METHOD FOR THE PURIFICATION OF TRIORGANOPHOSPHITES BY TREATMENT WITH A BASIC ADDITIVE INVISTA NORTH AMERICA S.A R.L. (US) 2010-03-25 US disclosed
US-7629484-B2 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A.R.L. (US) 2009-12-08 US disclosed
US-7629484-B2 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A.R.L. (US) 2009-12-08 US disclosed
US-20070219386-A1 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A R.L. (US) 2007-09-20 US disclosed
US-20070219386-A1 Method for the purification of triorganophosphites by treatment with a basic additive INVISTA NORTH AMERICA S.A R.L. (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219386-A1 Method for the purification of triorganophosphites by treatment with a basic additive HRH3, PHOSPHO1, HRH4 TP53 3729/4885TDP1 2668/4885ACHE 620/4885
US-20100076212-A1 METHOD FOR THE PURIFICATION OF TRIORGANOPHOSPHITES BY TREATMENT WITH A BASIC ADDITIVE HRH3, PHOSPHO1, HRH4 TP53 3729/4885TDP1 2668/4885ACHE 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.